- Conditions
- Clonal Cytopenia of Undetermined Significance
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Canakinumab, Chest Radiography, Echocardiography, Placebo Administration, Quality-of-Life Assessment
- Procedure · Drug · Other
- Lead sponsor
- Uma Borate
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 6
- States / cities
- Miami, Florida • New York, New York • Columbus, Ohio + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 541
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
- Interventions
- Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging of the Brain with and without Contrast, Monalizumab, Oleclumab, Radiation Therapy
- Radiation · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 56
- States / cities
- Atlanta, Georgia • Augusta, Georgia • Boise, Idaho + 42 more
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Recurrent Cutaneous Melanoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography, Surgical Procedure, VLP-encapsulated TLR9 Agonist CMP-001
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 187
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 134 more
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Ivonescimab, Magnetic Resonance Imaging, Sacituzumab Govitecan
- Procedure · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 41
- States / cities
- Berkeley, California • Palo Alto, California • Sacramento, California + 35 more
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Primary Central Nervous System Neoplasm, Xeroderma Pigmentosum
- Interventions
- Biospecimen Collection, Ipilimumab, Nivolumab
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 25 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more
- Conditions
- Meningitis, Meningococcal Infection
- Interventions
- Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 15 Years to 23 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 5 more
- Conditions
- Covid19
- Interventions
- Questionnaires and Patient Reported Outcomes (PROs), Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR), Blood Samples for Biomarkers, High Resolution Computed Tomography, Physical Exam and Vital Signs, Medical Research Council Sum Score, Hand Grip Strength, Spirometry, Diffusing Capacity of Carbon Monoxide, 6 Minute Walk Test, Sit to Stand (STS) Measurement
- Other · Diagnostic Test · Genetic
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • New York, New York • Houston, Texas
- Conditions
- Lymphoma
- Interventions
- biologic sample preservation procedure
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 203
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 137 more
- Conditions
- Recurrent Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
- Interventions
- Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging, Optical Coherence Tomography
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 27
- States / cities
- Aurora, Colorado • Coral Gables, Florida • Deerfield Beach, Florida + 19 more
- Conditions
- Infections, Meningococcal
- Interventions
- Nimenrix, Blood sampling
- Biological · Procedure
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 15 Years to 30 Years
- Enrollment
- 818 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 10
- States / cities
- Daly City, California • Fairfield, California • Redwood City, California + 6 more
- Conditions
- Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, Renal Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Weeks and older
- Enrollment
- 6,035 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Orange, Florida • Bethesda, Maryland + 2 more
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- biologic sample preservation procedure
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 1,294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 292
- States / cities
- Fort Smith, Arkansas • Berkeley, California • Burbank, California + 192 more
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Carfilzomib, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Sotorasib
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Duarte, California • Irvine, California
- Conditions
- Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Piflufolastat, PSMA PET/CT Scan, PSMA PET/MRI scan, Biospecimen Collection, Electronic Health Record Review
- Drug · Procedure · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- HPV
- Interventions
- Gardasil-9, Lidocaine injection, Lorazepam
- Biological · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Atezolizumab, Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 198
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 157 more
- Conditions
- Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Cytarabine, Echocardiography Test, Electrocardiogram, Fludarabine Phosphate, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate, Multigated Acquisition Scan, Prednisolone, Prednisone, Revumenib, Vincristine Sulfate
- Procedure · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Month to 6 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more
- Conditions
- Healthy
- Interventions
- Probiotic
- Dietary Supplement
- Lead sponsor
- Lallemand Health Solutions
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
- Interventions
- Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803, Ventana PD-L1 (SP263 or SP142) assay
- Biological · Drug · Device
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bone Loss
- Interventions
- Amount of PDGF-BB in PRF preparation vs. GEM21, Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation, Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes, Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Prostate Cancer
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Leukemia, Lymphoma
- Interventions
- biologic sample preservation procedure
- Other
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 0 Years to 120 Years
- Enrollment
- 1,873 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 214
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 156 more
- Conditions
- BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
- Interventions
- Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 12 Months to 25 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Congenital Anomaly, Pediatric Cancer
- Interventions
- Whole Genome Sequencing, Questionnaire Administration, Biospecimen collection, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 0 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas